The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Know AML webinar | Closing remarks and Q&A
Charles Craddock
June 5, 2025
Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience addressed by the chair, Charles Craddock, physician at Queen Elizabeth Hospital Birmingham and Know AML Ambassador; Gail J. Roboz, physician at Weill Cornell Medicine and Know AML Ambassador; and Ralph Hills, Know AML Chair.
Professor Craddock shared key takeaways from the webinar, emphasizing:
- The role of mutation testing in diagnosing AML, identifying subtypes and risks, and in guiding treatment decisions, both within and outside a clinical trial
- The importance of selecting the most appropriate method for testing mutations
- The value of open and clear communication between physicians and patients to make decisions together
The speakers then addressed questions from the audience.
This independent educational activity is supported by Thermo Fisher Scientific.
All content was developed independently by the faculty. The funder was allowed no influence on the content.
